This is important in light of the attempts to assess the feasibility of using both the levels of GOLPH3 and the inhibition of EGFR glycosylation as tools to downregulate EGFR signaling and sensitize cancer cells to anticancer therapies [73,74,75]. The gene discussed is GOLPH3; the disease is cancer.